Search

Your search keyword '"Vargas M"' showing total 13 results
Start Over Author "Vargas M" Journal atherosclerosis
13 results on '"Vargas M"'

3. The cardiometabolic characteristics of the premorbid metabolic syndrome in women, data from the IBERICAN study

Author

Frías vargas, M., primary, Pallarés Carratalá, V., additional, Díaz Rodríguez, A., additional, Cinza Sanjurjo, S., additional, Prieto Díaz, M.A., additional, García Vallejo, O., additional, García Lerín, A., additional, López Uriarte, B., additional, Rey Aldana, D., additional, Llisterri Caro, J.L., additional, Amorós Barber, T., additional, Antelo Pais, P., additional, Arribas Aguirregaviria, J., additional, Badimón Maestro, J.J., additional, Blanco Rodríguez, R., additional, Cano Cabo, E.M., additional, Celemín Colomina, I., additional, Del Toro González, O., additional, Escobar Cervantes, C., additional, and Espinosa García, J., additional

Published
2018
Full Text
View/download PDF

4. Does the family medicine specialist use the search for subclinical arteriosclerosis in his clinical practice?

Author

Frías vargas, M., primary, García vallejo, O., additional, Carrasco carrasco, E., additional, Ramírez torres, J.M., additional, Caballer rodilla, J., additional, Gil, I. Gil, additional, Aicart bort, M.D., additional, Casado casado, P., additional, Babiano fernández, M.A., additional, Cabrera ferriols, M.A., additional, García Fernández, P.J., additional, Rodríguez gonzález, A., additional, López téllez, A., additional, Vázquez gómez, N., additional, Pietrosanto, T., additional, Infantes Cordova, L.Y., additional, Fuentes domínguez, D., additional, Mayorga criado, A., additional, Perdomo garcía, F.J., additional, and López Uriarte, B., additional

Published
2018
Full Text
View/download PDF

5. Dyslipidemia and cardiovascular risk factors, data from the IBERICAN study

Author

Frías Vargas, M., primary, Díaz Rodríguez, A., additional, Capón Álvarez, J., additional, Buenaventura Felix Tavera, I., additional, García-Norro Herreros, F.J., additional, Fierro González, D., additional, Cinza Sanjurjo, S., additional, Prieto Díaz, M.A., additional, Pallarés Carratalá, V., additional, Rey Aldana, D., additional, Llisterri Caro, J.L., additional, García Vallejo, O., additional, García Lerín, A., additional, López Uriarte, B., additional, Fernández Fernández, L., additional, Fernández Valverde, D., additional, Ferrer Royo, M., additional, García Del Río, E., additional, García Romanos, F., additional, Gómez Montes, C., additional, and Gonzales Portal, L., additional

Published
2018
Full Text
View/download PDF

6. Circulating metabolomic profile indicates mitochondrial dysfunction in HIV-dyslipidemia

Author

rull aixa, A., primary, Rodríguez-Gallego, E., additional, Gómez, J., additional, Domingo, P., additional, Ferrando-MartíneZ, S., additional, Peraire, J., additional, Viladés, C., additional, Veloso, S., additional, López-Dupla, M., additional, Beltrán-Debón, R., additional, Alba, V., additional, Vargas, M., additional, Castellano, A., additional, Leal, M., additional, Pacheco, Y., additional, Ruiz-Mateos, E., additional, Gutiérrez, F., additional, and Vidal, F., additional

Published
2018
Full Text
View/download PDF

7. Risk of suffering from dyslipidaemia patients included in the IBERICAN study

Author

Díaz Rodríguez, A., primary, Frias Vargas, M., additional, Medez Rodriguez, E., additional, Mahmoud Atouitoui, O., additional, Felix Taveras, Ib, additional, Lopez Gil, Ja, additional, Tirado Moliner, Jm, additional, Torres Moreno, P., additional, Tramontano, A., additional, Vazquez Gómez, N., additional, Botella Garcia, M.C., additional, Caballar Rodilla, J., additional, Castillo Meroño, J., additional, Cols Segarra, C., additional, Contreras Torres, Ja, additional, De Santiago Nocito, Am, additional, Gutierres Montero, Jl, additional, Elorza Olabegoia, I., additional, Fidalgo Gonzalez, A., additional, and López Uriarte, B., additional

Published
2018
Full Text
View/download PDF

8. Effects on the renal profile of pitavastatin treatment in dyslipidemic patients, data from the REINA study

Author

Díaz Rodríguez, A., primary, Crespo Garcia, N., additional, Felix Taveras, Ib, additional, Frías Vargas, M., additional, Minniti, C., additional, Mendez Rodriguez, E., additional, Mahmoud Atoui, O., additional, Rodriguez Arroyo, La, additional, Veitia Suarez, Mz, additional, Barrenechea Fernandez, M.J., additional, Capón Alvarez, J., additional, Lumbreras Gonzalez, V., additional, Martinez Garcia, Fv, additional, Mandojana, J.Marinez DE., additional, Leon Regueras, J., additional, Marinez Canel, C., additional, Feliz Fernandez, N., additional, Seco Diaz, D., additional, Peleteiro Cobo, B., additional, and Pintó Sala, X., additional

Published
2018
Full Text
View/download PDF

9. Dyslipidemia profile and degree of control, data from the IBERICAN study

Author

Díaz Rodríguez, A., primary, Frias Vargas, M., additional, méndez Rodríguez, E., additional, Mahmoud Atoui, O., additional, Badimón Maestro, Jj, additional, crespo Garcia, N., additional, Capón Álvarez, J., additional, ruiz garcia, A., additional, palomo del arco, J., additional, heras hito, Ja, additional, Jimenez Muñoz, B., additional, Martín Valss, I., additional, Lires Rodriguez, C., additional, Medina Cano, Pa, additional, Peiró morant, Jf, additional, Riesgo Escudero, Se, additional, Rodó Bernardó, R., additional, Sanchez Esquivel, E., additional, Seoane novás, A., additional, and Sierra tapia, J., additional

Published
2018
Full Text
View/download PDF

10. Effects on the glycemic profile of pitavastatin treatment in dyslipidemic patients, data from the REINA study

Author

Díaz Rodríguez, A., primary, Mendez Rodriguez, E., additional, Crespo García, N., additional, Frias Vargas, M., additional, Felix Taveras, Ib, additional, Rodriguez Arroyo, La, additional, Capón Alvarez, J., additional, Minniti, C., additional, Mahmoud Atoui, O., additional, Veitia Suarez, Mz, additional, Vazquez Mallada, D., additional, Fierro González, D., additional, De Abajo Olea, S., additional, Lumbreras González, V., additional, Martinez DE Mandojana, J., additional, Garcia-Norro Herreros, Fj, additional, Pascual Fuster, V., additional, León Regueras, J., additional, Barrenechea Fernandez, M.J., additional, and Pintó Sala, X., additional

Published
2018
Full Text
View/download PDF

12. A new variant (c.1A>G) in LDLRAP1 causing autosomal recessive hypercholesterolemia: Characterization of the defect and response to PCSK9 inhibition.

Author

Rodríguez-Jiménez C, Gómez-Coronado D, Frías Vargas M, Cerrato F, Lahoz C, Saban-Ruiz J, González-Nieto D, Lasunción MA, Mostaza JM, and Rodríguez-Nóvoa S

Subjects
Humans, Male, Middle Aged, Hyperlipoproteinemia Type III, Adaptor Proteins, Signal Transducing genetics, Antibodies, Monoclonal, Humanized therapeutic use, Anticholesteremic Agents therapeutic use, Hypercholesterolemia drug therapy, Hypercholesterolemia genetics, Mutation, PCSK9 Inhibitors
Abstract

Background and Aims: Autosomal recessive hypercholesterolemia (ARH) is a rare disorder caused by mutations in LDLRAP1, which impairs internalization of hepatic LDL receptor (LDLR). ARH patients respond relatively well to statins or the combination of statins and Ezetimibe, but scarce and variable data on treatment with PCSK9 inhibitors is available. We aimed to identify and characterize the defect in a hypercholesterolemic patient with premature cardiovascular disease and determine the response to lipid-lowering treatment., Methods and Results: Gene sequencing revealed a homozygous c.1A > G:p.? variant in LDLRAP1. Primary lymphocytes were isolated from the ARH patient, one control and two LDLR-defective subjects, one LDLR:p.(Cys352Ser) heterozygote and one LDLR:p.(Asn825Lys) homozygote. The patient had undetectable full-length ARH protein by Western blotting, but expressed a lower-than-normal molecular weight peptide. LDLR activity was measured by flow cytometry, which showed that LDL binding and uptake were reduced in lymphocytes from the ARH patient as compared to control lymphocytes, but were slightly higher than in those from the LDLR:p.(Cys352Ser) heterozygote. Despite the analogous internalization defect predicted in ARH and homozygous LDLR:p.(Asn825Lys) lymphocytes, LDL uptake was higher in the former than in the latter. LDL-cholesterol levels were markedly reduced by the successive therapy with Atorvastatin and Atorvastatin plus Ezetimibe, and the addition of Evolocumab biweekly decreased LDL-cholesterol by a further 39%., Conclusions: The LDLRAP1:c.1A > G variant is associated with the appearance of an N-terminal truncated ARH protein and to reduced, although still significant, LDLR activity in lymphocytes. Residual LDLR activity may be relevant for the substantial response of the patient to Evolocumab., (Copyright © 2019 Elsevier B.V. All rights reserved.)

Published
2019
Full Text
View/download PDF

13. Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy.

Author

Rodríguez-Gallego E, Gómez J, Domingo P, Ferrando-Martínez S, Peraire J, Viladés C, Veloso S, López-Dupla M, Beltrán-Debón R, Alba V, Vargas M, Castellano AJ, Leal M, Pacheco YM, Ruiz-Mateos E, Gutiérrez F, Vidal F, and Rull A

Subjects
Adult, Anti-Retroviral Agents therapeutic use, Dyslipidemias metabolism, Female, Humans, Male, Metabolomics, Middle Aged, Predictive Value of Tests, Anti-Retroviral Agents adverse effects, Cholesterol blood, Dyslipidemias blood, Dyslipidemias chemically induced, HIV Infections drug therapy, Metabolome, Triglycerides blood
Abstract

Background and Aims: Dyslipidemia in HIV-infected patients is unique and pathophysiologically associated with host factors, HIV itself and the use of antiretroviral therapy (ART). The use of nuclear magnetic resonance spectroscopy (NMR) provides additional data to conventional lipid measurements concerning the number of lipoprotein subclasses and particle sizes., Methods: To investigate the ability of lipoprotein profile, we used a circulating metabolomic approach in a cohort of 103 ART-naive HIV-infected patients, who were initiating non-nucleoside analogue transcriptase inhibitor (NNRTI)-based ART, and we subsequently followed up these patients for 36 months. Univariate and multivariate analyses were performed to evaluate the predictive power of NMR spectroscopy., Results: VLDL-metabolism (including VLDL lipid concentrations, sizes, and particle numbers), total triglycerides and lactate levels resulted in good classifiers of dyslipidemia (AUC 0.903). Total particles/HDL-P ratio was significantly higher in ART-associated dyslipidemia compared to ART-normolipidemia (p = 0.001). Large VLDL-Ps were positively associated with both LDL-triglycerides (ρ 0.682, p < 0.001) and lactate concentrations (ρ 0.416, p < 0.001), the last one a marker of mitochondrial low oxidative capacity., Conclusions: Our data suggest that circulating metabolites have better predictive values for HIV/ART-related dyslipidemia onset than do the biochemical markers associated with conventional lipid measurements. NMR identifies changes in VLDL-P, lactate and LDL-TG as potential clinical markers of baseline HIV-dyslipidemia predisposition. Differences in circulating metabolomics, especially differences in particle size, are indicators of important derangements of mitochondrial function that are linked to ART-related dyslipidemia., (Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results